A Mab A Case Study In Bioprocess Development __top__ May 2026
The primary article you are looking for is titled "A-Mab: A Case Study in Bioprocess Development," published on October 30, 2009, by the CMC Biotech Working Group International Society for Pharmaceutical Engineering (ISPE)
Success in mAb development isn't just about high titers; it's about building a scalable, data-driven process that ensures purity from the very first flask. downstream purification details for your project? A Mab A Case Study In Bioprocess Development
Conclusion: The Future of mAb Bioprocessing
A Mab reached the clinic in 28 months from transfection – 6 months ahead of schedule. Today, it’s a blockbuster therapy. But the bioprocess continues to evolve. The team is now implementing continuous bioprocessing (perfused N-1 and connected capture) to boost productivity to 15 g/L and reduce COGS by 40%. The primary article you are looking for is
4.2 Filling and Finish
A Mab was filled into 10 mL Type I glass vials with a 20% overfill. The filling line operated at 300 vials/minute under Grade A isolators. Freeze-thaw studies showed stability for 5 cycles (typical for bulk freezing). Method: Low pH hold (pH 3
3.3 Viral Inactivation
- Method: Low pH hold (pH 3.5 for 60 min)
- Log reduction value (LRV): > 4.5 for model enveloped virus (X-MuLV).
The cell line development process involved several rounds of cloning and screening to identify a cell line with the desired characteristics, including: